Patent focus on new anti-obesity agents: September 1999 - February 2000

Bibliography

• WORLD HEALTH ORGANIZATION: Obesity: Preventingand Managing the Global Epidemic. World Health Organi-zation, Geneva (1998).
   Google Scholar
• ALLISON DB, FONTAINE KR, MANSON JE, STEVENS J,VANITALLIE TB: Annual deaths attributable to obesity in the United States. J. Am. Med. Assoc. (1999) 282:1530–1538.
   PubMed Web of Science ®Google Scholar
• EXPERT PANEL ON THE IDENTIFICATION, EVALUATION AND TREATMENT OF OVERWEIGHT IN ADULTS: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am. J. Clin. Nutr. (1998) 68:899–917.
   PubMed Web of Science ®Google Scholar
• BRAY GA, GREENWAY FL: Current and potential drugs for the treatment of obesity. Endocr. Rev. (1999) 20:805–875.
   PubMed Web of Science ®Google Scholar
• ••Extensive review of clinical data on anti-obesity drugs andexcellent discussion of central and peripheral pathways involved in the regulation of food intake.
   Google Scholar
• KORDIK CP, REITZ AB: pharmacological treatment of: therapeutic strategies. J. Med. Chem. (1999) 42:181–201.
   PubMed Web of Science ®Google Scholar
• •Extensive review of new anti-obesity therapies, especially I33-AR agonists.
   Google Scholar
• DUBE MG, XU B, KALRA PS, SNINSKY CA, KALRA SP: in neuropeptide Y and leptin signaling in obese ventromedial hypothalamic-lesioned rats. Brain Res. (1999) 816:38–46.
   PubMed Web of Science ®Google Scholar
• HOEBEL BG: Feeding: neural control of intake. Ann. Rev. Physic)]. (1971) 33:533–568.
   PubMed Web of Science ®Google Scholar
• BARSH GS, FAROOQI S, O'RAHILLY S: Genetics of body-weight regulation. Nature (2000) 404:644–651.
   PubMed Web of Science ®Google Scholar
• INUI A: Feeding and body weight regulation by hypothamic neuropeptides - mediation of the actions of leptin. Trends Neurosci. (1999) 22:62–67.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of neuropeptides involved infeeding.
   Google Scholar
• KALRA SP, DUBE MG, PU S et al.: Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. (1999) 20:68–100.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, WOODS SC, PORTE JR D, SEELEY RJ,BASKIN DG: Central nervous system control of food intake. Nature (2000) 404:661–671.
   PubMed Web of Science ®Google Scholar
• STANLEY BG, LEIBOWITZ SF: Neuropeptide Y: stimula-tion of feeding and drinking by injection into the paraventricular nucleus. Life ScL (1984) 35:2635–2642.
   PubMed Web of Science ®Google Scholar
• ••First report of the orexigenic effects of NPY. CJ, BRIGGS JE, HARKER S, GRACE M, LEVINE AS: Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am. J. Physiol (1994) 266:R1765–R1770.
   Google Scholar
• ROHNER-JEANRENAUD F: Neuroendocrine regulation of nutrient partitioning. Ann. NY Acad. Sci. (1999) 892:261–271.
   PubMed Web of Science ®Google Scholar
• ERICKSON JC, CLEGG KE, PALMITER RD: Sensitivity toleptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature (1996) 381:415–418.
   PubMed Web of Science ®Google Scholar
• KALRA SO, DUBE MG, SAHU A, PHELPS CO, KALRA PS:Neuropeptide Y secretion increases in the paraven-tricular nucleus in association with increased appetite. Proc. Natl. Acad. ScL USA (1991) 88:10931–10935.
   PubMed Web of Science ®Google Scholar
• STANLEY BG, KYRKOULI SE, LAMPERT S, LEIBOWITZ SF:Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides (1986) 7:1189–1192.
   PubMed Web of Science ®Google Scholar
• WILDING JPH, GILBEY SG, BAILEY CJ et al.: Increasedneuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocri-nology (1993) 132:1939–1944.
   PubMed Web of Science ®Google Scholar
• ERICKSON JC, HOLLOPETER G, PALMITER RD: Attenua-tion of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science (1996) 274:1704–1707.
   PubMed Web of Science ®Google Scholar
• MARIN-BIVENS CL, KALRA SP, OLSTER DH: Intraven-tricular injection of neuropeptide Y antisera curbs weight gain and feeding, and increases the display of sexual behaviors in obese Zucker female rats. Regul Pept. (1998) 75–76:327–334.
   Google Scholar
• GEHLERT DR: Role of hypothalamic neuropeptide Yinfeeding and obesity. Neuropeptides (1999) 33:329–338.
   PubMed Web of Science ®Google Scholar
• •Excellent review on the pharmacology of the known NPY receptor subtypes.
   Google Scholar
• GERALD C, WALKER MW, CRISCIONE L et al.: A receptorsubtype involved in neuropeptide-Y-induced food intake. Nature (1996) 382:168–171.
   PubMed Web of Science ®Google Scholar
• KUSHI A, SASAI H, KOIZUMI H, TAKEDA N, YOKOYAMA, NAKAMURA M: Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc. Nati Acad. Sci. USA (1998) 95:15659–15664.
   PubMed Web of Science ®Google Scholar
• PEDRAZZINI T, SEYDOUX J, KUNSTNER P et al: Cardio-vascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nature Med. (1998) 4:722–726.
   PubMed Web of Science ®Google Scholar
• NAVEILHAN P, HASSANI H, CANALS J et al.: Normalfeeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nature Med. (1999) 5:1188–1193.
   PubMed Web of Science ®Google Scholar
• MARSH DJ, HOLLOPETER G, KAFER KE, PALMITER RD: Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat. Med. (1998) 4:718–721.
   PubMed Web of Science ®Google Scholar
• KANATANI A, MASHIKO S, MURAI N eta].: Role of the Y1receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocri-nology (2000) 141:1011–1016.
   Google Scholar
• ISHIHARA A, TANAKA T, KANATANI A, FUKAMI T, IHARA, FUKURODA T: A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats. Am. J. Physiol (1998) 274:R1500–R1503.
   Google Scholar
• KANATANI A, KANNO T, ISHIHARA A et al: The novelneuropeptide Y Y1 receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem. Biophys. Res. Commun. (1999) 266: 88–91.
   PubMed Web of Science ®Google Scholar
• •Describes first orally active Y1-R antagonist.
   Google Scholar
• CRISCIONE L, RIGOLLIER P, BATZL-HARTMANN C et al: intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J. Clin. Invest. (1998) 102:2136–2145.
   PubMed Web of Science ®Google Scholar
• •Describes first Y5-R antagonist that decreases food intake in rats.
   Google Scholar
• DOODS H, GAIDA W, WIELAND HA, DOLLINGER H, SCHNORRENBERG G, ESSER F et al: BIIE0246: a selective and high affinity neuropeptide Y Y2 receptor antago-nist. Eur. J. Pharmacol (1999) 384:R3–R5.
   Web of Science ®Google Scholar
• MOUNTJOY KG, MORTRUD MT, LOW MJ, SIMERLY RB,CONE RD: Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol (1994) 8:1298–1308.
   PubMed Web of Science ®Google Scholar
• COWLEY MA, PRONCHUK N, FAN W, DINULESCU DM, COLMERS WF, CONE RD: Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraven-tricular nucleus: evidence of a cellular basis for the adipostat. Neuron (1999) 24:155–163.
   PubMed Web of Science ®Google Scholar
• ••Presents unified model for the hypothalamic control offeeding behavior.
   Google Scholar
• FAN W, BOSTON BA, KESTERSON RA, HRUBY VJ, CONERD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature (1997) 385:165–168.
   PubMed Web of Science ®Google Scholar
• YASWEN L, DIEHL N, BRENNAN MB, HOCHGESCH-WENDER U: Obesity in the mouse model of pro-opiomelanocortin deficiency responds to periph-eral melanocortin. Nature Med (1999) 5:1066–1070.
   PubMed Web of Science ®Google Scholar
• HUSZARD, LYNCH CA, FAIRCHILD-HUNTRESS V et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 88:131–141.
   PubMed Web of Science ®Google Scholar
• OLLMANN MM, WILSON BD, YANG Y-K et al.: Antago-nism of central melanocortin receptors in vitro and in vivo by Agouti-related protein. Science (1997) 278:135–138.
   PubMed Web of Science ®Google Scholar
• GRAHAM M, SHUTTER JR, SARMIENTO U, SAROSI I, STARK KL: Overexpression of AGRP leads to obesity in transgenic mice. Nat. Genet. (1997) 17:273–274.
   PubMed Web of Science ®Google Scholar
• LEBL M, KRCHNAK V, IBRAHIM G et al.: Solid-phase synthesis of large tetrahydroisoquinolinone arrays by two different approaches. Synthesis (1999) 11:1971–1978.
   Google Scholar
• SAKURAI T, AMEMIYA A, ISHII M et al.: Orexins and orexin receptors: a family of hypothalamic neuropep-tides and G protein-coupled receptors that regulate feeding behavior. Cell (1998) 92:573–585.
   PubMed Web of Science ®Google Scholar
• YAMANAKA A, SAKURAI T, KATSUMOTO T, YANAGI-SAWA M, GOTO K: Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res. (1999) 849:248–252.
   PubMed Web of Science ®Google Scholar
• CAI XJ, WIDDOWSON PS, HARROLD J et al.: Hypotha-lamic orexin expression: modulation by blood glucose and feeding. Diabetes (1999) 48: 2132–2137.
   PubMed Web of Science ®Google Scholar
• SAKURAI T: Orexins and orexin receptors: implication in feeding behavior. Regul. Pept. (1999) 85:25–30.
   PubMedGoogle Scholar
• JAIN MR, HORVATH TL, KALRA PS, KALRA SP: Evidence that NPY Y1 receptors are involved in stimulation of feeding by orexins (hypocretins) in sated rats. Regui Pept. (2000) 87:19–24.
   PubMedGoogle Scholar
• TRIVEDI P, YU H, MACNEIL DJ, VAN DER PLOEG LHT, GUAM X-M: Distribution of orexin receptor mRNA in the rat brain. FEBS Letters (1998) 438:71–75.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, RAMPEY AH, ROBACK PJ et al.: Efficacy and safety of long-term fluoxetine treatment of obesity - maximizing success. Obes. Res. (1995) 3:481S–490S.
   Google Scholar
• KITCHENER SJ, DOURISH CT: An examination of the behavioral specificity of hypophagia induced by 5-HT1B, 5-HT1C and 5-HT2 receptor agonists using the post-prandial satiety sequence in rats. Psychopharma-cology (1994) 113:369–377.
   PubMed Web of Science ®Google Scholar
• LUCAS JJ, YAMAMOTO A, SCEARCE-LEVIE K, SAUDOU F, HEN R: Absence of fenfluramine-induced anorexia and reduced c-fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J. Neurosci. (1998) 18:5537–5544.
   PubMed Web of Science ®Google Scholar
• TECOTT LH, SUN LM, AKANA SF et al.: Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature (1995) 374:542–546.
   PubMed Web of Science ®Google Scholar
• VICKERS SP, CLIFTON PG, DOURISH CT, TECOTT LH: Reduced satiating effect of d-fenfluramine in 5-HT2C receptor mutant mice. Psychophar-macology (1999) 143:309–314.
   PubMed Web of Science ®Google Scholar
• MARTIN JR, BOS M, JENCK F et al.: 5-HT2C receptoragonists: pharmacological characteristics and therapeutic potential. J. Pharmacol Exp. Ther. (1998) 286:913–924.
   PubMed Web of Science ®Google Scholar
• NICHOLLS DG, LOCKE RM: Thermogenic mechanismsin brown fat. Physiol. Rev. (1984) 64:1–64.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ DE, NARDONE NA, SMILEY RM et al.: Distri-bution of I33-adrenoceptor mRNA in human tissues. Eur. J. Pharmacol., Mol. Pharmacol. Sect. (1995) 289:223–228.
   PubMed Web of Science ®Google Scholar
• CHAUDHRY A, GRANNEMAN JG: Differential regulationof functional responses by p-adrenergic receptor subtypes in brown adipocytes. Am. J. Physic)]. (1999) 277:R147–R153.
   Google Scholar
• RICQUIER D: Mitochondrial uncoupling proteins. Curr.Opin. Drug Dis. Dev. (1999) 2:497–504.
   PubMedGoogle Scholar
• LOWELL BB, SPIEGELMAN BM: Toward a molecular understanding of adaptive thermogenesis. Nature (2000) 404:652–660.
   PubMed Web of Science ®Google Scholar
• WEYER C, TATARANNI PA, SNITKER S, DANFORTH E JR,RAVUSSIN E: Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective i33-adrenoceptor agonist in humans. Diabetes (1998) 47:1555–1561.
   PubMed Web of Science ®Google Scholar
• WEIBEL EK, HADVARY P, HOCHULI E, KUPFER E, LENGSFELD H: Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J. Antibiot. (1987) 40:1081–1085.
   Google Scholar
• HADVARY P, SIDLER W, MEISTER W, VETTER W, WOLFERH: The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancre-atic lipase. J. Biol. Chem. (1991) 266:2021–2027.
   PubMed Web of Science ®Google Scholar
• LUETHI-PENG Q, MAERKI HP, HADVARY P: Identifica-tion of the active-site serine in human pancreatic lipase by chemical modification with tetrahydrolip-statin. FEBS Lett. (1992) 299:111–115.
   PubMed Web of Science ®Google Scholar
• HAUPTMAN J, GUERCIOLINI R, NICHOLS G: Orlistat: anovel treatment for obesity. Pennington Cent. Nutr. Ser. (1999) 9:530–547.
   Google Scholar
• DAVIDSON MH, HAUPTMAN J, DIGIROLAMO M et al:Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. J. Am. Med. Assoc. (1999) 281:235–242.
   PubMed Web of Science ®Google Scholar
• NAGLE DL, MCGRAIL SH, VITALE J et al: The mahogany protein is a receptor involved in suppression of obesity. Nature (1999) 398:148–152.
   PubMed Web of Science ®Google Scholar
• GUNN TM, MILLER KA, HE L et al.: The mouse mahogany locus encodes a transmembrane form of human attractin. Nature (1999) 398:152–156.
   PubMedGoogle Scholar
• HILL JO: Genetic and environmental contributions toobesity. Am. J. Clin. Nutr. (1998) 68:991–992.
   PubMed Web of Science ®Google Scholar
• HILL JO, PETERS JC: Environmental contributions to theobesity epidemic. Science (1998) 280:1371–1374.
   PubMed Web of Science ®Google Scholar